<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04214288</url>
  </required_header>
  <id_info>
    <org_study_id>D8530C00002</org_study_id>
    <nct_id>NCT04214288</nct_id>
  </id_info>
  <brief_title>A Comparative Study of AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer</brief_title>
  <acronym>SERENA-2</acronym>
  <official_title>SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase 2 Study Comparing the Efficacy and Safety of Oral AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is randomized, open-label, parallel-group, multicentre Phase 2 study aimed to&#xD;
      compare the efficacy and safety of oral AZD9833 versus intramuscular (IM) fulvestrant in&#xD;
      women with advanced breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post-menopausal women with histologically or cytologically confirmed metastatic or&#xD;
      loco-regionally recurrent ER-positive HER2-negative breast cancer before randomization and&#xD;
      fulfilling all of the inclusion criteria and none of the exclusion criteria will be included.&#xD;
&#xD;
      After the screening visit and confirmation of eligibility, patients will be randomly assigned&#xD;
      in a 1:1:1:1 ratio to receive 1 of the following 4 treatments, consisting of 4-week treatment&#xD;
      cycles until disease progression (assessed by the Investigator as defined by Response&#xD;
      Evaluation Criteria in Solid Tumours [RECIST] version 1.1):&#xD;
&#xD;
        -  AZD9833 (Dose A)&#xD;
&#xD;
        -  AZD9833 (Dose B)&#xD;
&#xD;
        -  AZD9833 (Dose C)&#xD;
&#xD;
        -  Fulvestrant (500 mg) During the treatment period, patients will have scheduled visits&#xD;
           until treatment discontinuation. After the end of treatment, patients will attend 2&#xD;
           safety follow-up visits (at the time of treatment discontinuation and 28 days later) and&#xD;
           will continue to be followed for survival.&#xD;
&#xD;
      As of December 2020, the Sponsor stopped enrolment to Dose C.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 22, 2020</start_date>
  <completion_date type="Anticipated">December 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 24, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST) version 1.1</measure>
    <time_frame>From date of randomisation to date of objective disease progression or death (up to approximately 3 years)</time_frame>
    <description>Time from randomisation to objective disease progression (as assessed by RECIST) or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) assessed by the Investigator as defined by RECIST version 1.1</measure>
    <time_frame>From screening until disease progression (up to approximately 3 years)</time_frame>
    <description>The ORR is defined as the percentage of patients with at least 1 Investigator-assessed visit response of complete response (CR) or partial response (PR) prior to any evidence of progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR) assessed by the Investigator as defined by RECIST version 1.1</measure>
    <time_frame>From screening until disease progression (up to approximately 3 years)</time_frame>
    <description>The DoR will be defined as the time from the date of first documented response until date of documented progression or death in the absence of disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in tumour size at 16 weeks</measure>
    <time_frame>At Week 16</time_frame>
    <description>Percentage change in the sum of longest target lesions diameters at 16 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From the date of randomisation until death (up to approximately 3 years)</time_frame>
    <description>The OS is defined as the time from randomisation to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate at 24 weeks (CBR24)</measure>
    <time_frame>At Week 24</time_frame>
    <description>Percentage of patients with CBR (defined as best objective response of CR, PR or stable disease [SD] at 24 weeks).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of AZD9833 and, if appropriate, metabolite(s)</measure>
    <time_frame>Cycle 1 Day 15 (pre- and post-dose) and Cycle 2 Day 1 (pre-dose), (each cycle is 28 days in length)</time_frame>
    <description>To evaluate the pharmacokinetic (PK) profile of AZD9833 in this patient population at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in ER and PgR expression and Ki67 labelling index.</measure>
    <time_frame>From baseline to Cycle 2 Day 1 (each cycle is 28 days in length).</time_frame>
    <description>The pharmacodynamics of AZD9833 and fulvestrant in a subgroup of patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Health Related Quality of Life (HRQoL)</measure>
    <time_frame>From Day 1 until end of treatment and safety follow up (up to approximately 3 years)</time_frame>
    <description>To evaluate the effect of AZD9833 and fulvestrant on the patients' health-related quality of life, as assessed by patient completed HRQoL questionnaires.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Advanced ER-Positive HER2-Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>AZD9833 Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will receive AZD9833 (Dose A).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD9833 Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will receive AZD9833 (Dose B).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD9833 Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will receive AZD9833 (Dose C).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fulvestrant 500 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients will receive Fulvestrant (500 mg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9833</intervention_name>
    <description>Dosage formulation: AZD9833 tablets will be administered orally.</description>
    <arm_group_label>AZD9833 Dose A</arm_group_label>
    <arm_group_label>AZD9833 Dose B</arm_group_label>
    <arm_group_label>AZD9833 Dose C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>Dosage formulation: Fulvestrant will be administered via intramuscular (IM) injection.</description>
    <arm_group_label>Fulvestrant 500 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Post-menopausal female patients aged at least 18 years.&#xD;
&#xD;
          -  Metastatic or loco-regionally recurrent ER-positive HER2-negative adenocarcinoma of&#xD;
             the breast.&#xD;
&#xD;
          -  Radiological or other objective evidence of progression on or after the last systemic&#xD;
             therapy prior to starting study treatment.&#xD;
&#xD;
          -  Patients must have at least 1 lesion, not previously irradiated, that can be measured&#xD;
             accurately at baseline as ≥10 mm in the longest diameter or in absence of measurable&#xD;
             disease as defined above, at least 1 lytic or mixed (lytic+sclerotic) bone lesion.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG)/World Health Organisation (WHO) performance&#xD;
             status 0 to 1.&#xD;
&#xD;
          -  Prior endocrine therapy as follows:&#xD;
&#xD;
               1. Recurrence or progression on at least one line of endocrine therapy&#xD;
&#xD;
               2. No more than 1 line of endocrine therapy for advanced disease&#xD;
&#xD;
               3. No more than 1 line of chemotherapy for advanced disease&#xD;
&#xD;
               4. Prior treatment with CDK4/6 inhibitors is permitted&#xD;
&#xD;
               5. No prior treatment with fulvestrant, oral selective oestrogen receptor degrader&#xD;
                  (SERD), or related therapies&#xD;
&#xD;
          -  Inclusion criterion for the paired tumour biopsy research subgroup:&#xD;
&#xD;
        Washout from prior tamoxifen: 4 months to elapse from last tamoxifen dose to pre-dose&#xD;
        on-study biopsy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Intervention with any of the following:&#xD;
&#xD;
          -  Any cytotoxic chemotherapy, investigational agents or other anti-cancer drugs for the&#xD;
             treatment of breast cancer from a previous treatment regimen or clinical study within&#xD;
             14 days of the first dose of study treatment.&#xD;
&#xD;
          -  Use of systemic oestrogen-containing hormone replacement therapy within 6 months prior&#xD;
             to the first dose of study treatment.&#xD;
&#xD;
          -  Medications or herbal supplements known to be strong inhibitors/inducers of cytochrome&#xD;
             P450 3A4/5 and sensitive CYP2B6 substrates, and drugs which are substrates of CYP2C9&#xD;
             and/or CYP2C19 which have a narrow therapeutic index or inability to stop use within&#xD;
             the washout period prior to receiving the first dose of study treatment.&#xD;
&#xD;
          -  Drugs that are known to prolong QT and have a known risk of torsades de pointes.&#xD;
&#xD;
          -  The following cardiovascular criteria: QTcF &gt;470 ms, resting heart rate &lt;45 bpm,&#xD;
             clinically significant abnormalities of resting electrocardiogram, uncontrolled&#xD;
             hypertension, symptomatic hypotension, factors that increase the risk for QTc&#xD;
             prolongation, left ventricular ejection fraction &lt;50%.&#xD;
&#xD;
          -  Radiotherapy with a limited field of radiation for palliation within 1 week of dosing,&#xD;
             or to &gt; 30% of bone marrow or a wide field within 4 weeks of dosing.&#xD;
&#xD;
          -  Major surgical procedure or significant traumatic injury.&#xD;
&#xD;
          -  Presence of life-threatening metastatic visceral disease or uncontrolled central&#xD;
             nervous system metastatic disease.&#xD;
&#xD;
          -  Inadequate bone marrow reserve or organ function.&#xD;
&#xD;
          -  Refractory nausea and vomiting, uncontrolled chronic gastrointestinal diseases,&#xD;
             inability to swallow the formulated product, or previous significant bowel resection&#xD;
             that would preclude adequate absorption of AZD9833.&#xD;
&#xD;
          -  History of hypersensitivity to active or inactive excipients of AZD9833 or&#xD;
             fulvestrant.&#xD;
&#xD;
          -  Previous randomisation in the present study.&#xD;
&#xD;
          -  Women of childbearing potential.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brasschaat</city>
        <zip>2930</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Haine-Saint-Paul</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Libramont-Chevigny</city>
        <zip>6800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Batumi</city>
        <zip>6000</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tbilisi</city>
        <zip>'0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tbilisi</city>
        <zip>'0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tbilisi</city>
        <zip>'0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tbilisi</city>
        <zip>0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10707</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaposvár</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kecskemét</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pécs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nahariya</city>
        <zip>22100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Petah Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Messina</city>
        <zip>98158</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Umbria</city>
        <zip>5100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Piła</city>
        <zip>64-920</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-021</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Skorzewo</city>
        <zip>60-185</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Łódź</city>
        <zip>93-513</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Almada</city>
        <zip>2805-267</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1400-038</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1449-005</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1998-018</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kazan</city>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krasnodar</city>
        <zip>350040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kursk</city>
        <zip>305035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>123056</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357502</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197082</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Volgograd</city>
        <zip>400138</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08190</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cherkasy</city>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chernivtsі</city>
        <zip>58013</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>03039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>M. Kyiv</city>
        <zip>02094</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>S. Khodosivka</city>
        <zip>08173</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uzhhorod</city>
        <zip>88000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Mexico</country>
  </removed_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 27, 2019</study_first_submitted>
  <study_first_submitted_qc>December 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Open-Label</keyword>
  <keyword>Parallel-Group</keyword>
  <keyword>Fulvestrant</keyword>
  <keyword>ER-Positive HER2-Negative Breast Cancer</keyword>
  <keyword>Metastatic</keyword>
  <keyword>AZD9833</keyword>
  <keyword>Oral SERD</keyword>
  <keyword>Camizestrant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment:&#xD;
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at:&#xD;
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at:&#xD;
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

